Literature DB >> 1890165

Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin.

N Kondo1, T Ozawa, K Mushiake, F Motoyoshi, T Kameyama, K Kasahara, H Kaneko, M Yamashina, Y Kato, T Orii.   

Abstract

The proliferative responses and the immunoglobulin production of peripheral blood mononuclear cells to pokeweed mitogen were dose-dependently suppressed by sulfonated intravenous immunoglobulin (IVIG), polyethylene glycol-treated IVIG, pH 4-treated IVIG, or human gamma-globulin, but they were not or only slightly suppressed by human serum albumin or pepsin-treated IVIG. Moreover, the suppression of immunoglobulin production by sulfonated IVIG, polyethylene glycol-treated IVIG, or pH 4-treated IVIG was seen in the cases in which B cells preincubated with IVIGs were cocultured with T cells and monocytes preincubated with or without IVIGs and in the cases in which monocytes preincubated with IVIGs were cocultured with T cells and B cells preincubated with or without IVIGs. However, in the cases in which only T cells were preincubated with IVIGs, immunoglobulin production was not suppressed. The suppression of the monocyte function by IVIGs tended to be less than the suppression of the B-cell function by IVIGs. Moreover, the suppression by IVIGs was blocked by anti-human IgG Fc. Our results suggest that IVIGs suppress the immunoglobulin production of lymphocytes through suppression of the B-cell function and the antigen presenting-cell function by attachment of IVIGs to Fc receptors of B-cell membranes and antigen presenting-cell membranes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890165     DOI: 10.1007/bf00918683

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  15 in total

Review 1.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

2.  Isolation of B and T lymphocytes by nylon fiber columns.

Authors:  C Werner; P T Klouda; M C Corréa; P Vassalli; M Jeannet
Journal:  Tissue Antigens       Date:  1977-04

3.  Differences among available immunoglobulin preparations for intravenous use.

Authors:  F Skvaril; A Gardi
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

4.  Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

Authors:  L Cook; J F Howard; J D Folds
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

5.  Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura.

Authors:  T Tsubakio; Y Kurata; S Katagiri; Y Kanakura; T Tamaki; J Kuyama; Y Kanayama; T Yonezawa; S Tarui
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

6.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

7.  Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis.

Authors:  J Sany; J Clot; M Bonneau; M Andary
Journal:  Arthritis Rheum       Date:  1982-01

8.  Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study.

Authors:  T W Jungi; M Santer; P G Lerch; S Barandun
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

9.  Competence of B cells for T-cell help in pokeweed mitogen-induced immunoglobulin production.

Authors:  N Kondo; T Orii; H Uetake
Journal:  Clin Immunol Immunopathol       Date:  1983-02

10.  IgG therapy in systemic lupus erythematosus--two case reports.

Authors:  G Gaedicke; W M Teller; E Kohne; R Dopfer; D Niethammer
Journal:  Blut       Date:  1984-06
View more
  13 in total

1.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

Authors:  M Toyoda; X Zhang; A Petrosian; O A Galera; S J Wang; S C Jordan
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

4.  Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

Authors:  L Padet; I St-Amour; É Aubin; R Bazin
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

5.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 6.  Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.

Authors:  S C Jordan; M Toyoda
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 7.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

9.  In vitro synthesis of human IgE is suppressed by human IgG.

Authors:  H Haas; M Schlaak
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

10.  Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.